Skip to main content

Advertisement

Figure 4 | Molecular Brain

Figure 4

From: Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1

Figure 4

Pharmacological enhancement of mGlu1 receptors causes a prolonged symptomatic benefit in SCA1 mice. Motor performance on the rotarod in SCA1 mice with severe motor impairment at different times following a single injection of vehicle or Ro0711401 is shown in (A), where values are means ± S.E.M. of 6 mice per group. *p < 0.05 vs. the corresponding values at time 0; Two-way ANOVA for repeated measures + Fisher’s LSD; F(7,35) = 2.48, F(1,10) = 21.003, and F(7,35) = 2.321 for time, treatment, and time x treatment, respectively. Motor performance in SCA1 mice with mild impairment treated daily with Ro0711401 is shown in (B), where values are means ± S.E.M. of 6 mice per group. *p < 0.05 vs. the corresponding pre-treatment values; Two-way ANOVA for repeated measures + Fisher’s LSD; F(5,15) = 4.248, F(1,11) = 37.408 and F(5,15) = 6.078 for time, treatment and time x treatment, respectively. The lack of motor effect of single injection of Ro0711401 in wild-type littermates is shown in (C), where values are means ± S.E.M. of 4 mice per group.

Back to article page